Search Results

Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round.

AlzeCure Pharma AB announced that its CEO Martin Jönsson will present the company at the investor conference BioCapitalEurope 2024, which is organized by EQT Life Sciences.

Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the completion of its acquisition by EQT IX fund and funds managed by the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.

Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund and the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.

The EQT Mid Market US fund and the EQT Mid Market Asia III fund (jointly “EQT”) have entered into an agreement to sell Clinical Innovations (the “Company”) to LABORIE Medical Technologies (“LABORIE”) for an Enterprise Value of USD 525m

Agomab Therapeutics NV announced the closing of a $100 million Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences, Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

The EQT IX fund and the Private Equity business within Goldman Sachs Asset Management have agreed to acquire Parexel, a leading global clinical research organization from Pamplona Capital Management for an enterprise value of USD 8.5 billion.

Residents, Communities and Organizations Throughout EQT’s Operating Areas Benefit from the Foundation’s Strong Support